A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
Recruiting now
Conditions studied: Hemolytic Disease of the Fetus and Newborn
In brief
The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neonates (baby just after birth) of pregnant participants who are at risk for hemolytic disease of the fetus and newborn (HDFN) and receiving standard of care (SoC). HDFN is a blood disease that occurs in babies before birth or just after birth when the blood types of the pregnant individual and babies are incompatible, thus resulting in fast breakdown of red blood cells (RBCs) of the fetus/baby.
Key facts
- Study ID
- NCT07194070
- Run by
- Janssen Research & Development, LLC
- People needed
- 175
- Starts
- 2025-12-17
- Expected to finish
- 2030-09-30
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Pregnant with an estimated gestational age (GA) (based on ultrasound dating) up to week 24
- History of a previous alloimmunized pregnancy that included at least one of the following: Fetal anemia diagnosed by middle cerebral artery (MCA) doppler ultrasound; Received greater than or equal to (>=) 1 intrauterine transfusion (IUT) as a result of hemolytic disease of the fetus and newborn (HDFN); Fetal hydrops; Stillbirth or fetal demise with fetal or placental pathology indicative of HDFN; Neonatal exchange transfusion due to HDFN; Neonatal simple transfusion due to HDFN; Neonatal hyperbilirubinemia due to HDFN; Positive direct antiglobulin test (DAT) in neonate
- Documented presence of maternal alloantibody based on local laboratory results during current pregnancy
- Evidence of an antigen-positive fetus corresponding to the current maternal alloantibody: Fetal antigen status confirmed by cell-free fetal DNA (cffDNA); OR Fetal antigen status confirmed by amniocentesis; OR Paternal genotype confirmed
- Pregnant participant or a legally acceptable representative has provided informed consent (per local regulations or ethics committee requirements) for the collection and use of their medical data and the medical data for their corresponding fetuses/neonates/infants/children
You may not qualify if…
- Participant actively participating in an interventional trial of an investigational agent
- At risk for HDFN due to ABO being the sole alloimmunization antigen in the current pregnancy (that is, ABO plus another antigen is permissible)
Where it is running
- Riley Children s Hospital — Indianapolis, Indiana, United States (enrolling)
- University of Rochester Medical Center — Rochester, New York, United States (enrolling)
- University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
- Oregon Health And Science University — Portland, Oregon, United States (enrolling)
- Baylor College of Medicine — Houston, Texas, United States (enrolling)
- The Royal Women's Hospital — Parkville, Australia (enrolling)
- Mater Misericordiae Ltd — South Brisbane, Australia (enrolling)
- Universitair Ziekenhuis Gent — Ghent, Belgium (enrolling)
- Universitair Ziekenhuis Leuven — Leuven, Belgium (enrolling)
- State University of Campinas Joao Bennini — Campinas, Brazil (enrolling)
- Interdiszip Schwerpunkt fur Hamostaseologie — Giessen, Germany (enrolling)
- Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggiore Policlinico — Milan, Italy (enrolling)
- Fondazione Policlinico Universitario A Gemelli IRCCS — Roma, Italy (enrolling)
- Hosp Univ Vall D Hebron — Barcelona, Spain (enrolling)
- Birmingham Women's Hospital — Birmingham, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.